These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9804058)

  • 41. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
    Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
    Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Implication of poly (ADP-ribose) polymerase (PARP) in neurodegeneration and brain energy metabolism. Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide.
    Cosi C; Marien M
    Ann N Y Acad Sci; 1999; 890():227-39. PubMed ID: 10668429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
    Robertson RG; Clarke CA; Boyce S; Sambrook MA; Crossman AR
    Brain Res; 1990 Oct; 531(1-2):95-104. PubMed ID: 2289139
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():27-38. PubMed ID: 25046277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.
    Yabuki Y; Ohizumi Y; Yokosuka A; Mimaki Y; Fukunaga K
    Neuroscience; 2014 Feb; 259():126-41. PubMed ID: 24316474
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
    Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
    Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
    Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
    Gagnon C; Gomez-Mancilla B; Bédard PJ; Di Paolo T
    Neurosci Lett; 1993 Nov; 163(1):31-5. PubMed ID: 7905197
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-apoptotic effect of modified Chunsimyeolda-tang, a traditional Korean herbal formula, on MPTP-induced neuronal cell death in a Parkinson's disease mouse model.
    Li H; Park G; Bae N; Kim J; Oh MS; Yang HO
    J Ethnopharmacol; 2015 Dec; 176():336-44. PubMed ID: 26593210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circadian determinations of cortisol, prolactin and melatonin in chronic methyl-phenyl-tetrahydropyridine-treated monkeys.
    Barcia C; Bautista V; Sánchez-Bahillo A; Fernández-Villalba E; Navarro-Ruis JM; Barreiro AF; Poza Y Poza M; Herrero MT
    Neuroendocrinology; 2003 Aug; 78(2):118-28. PubMed ID: 12915764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increase of plasma adrenocorticotrophin and cortisol in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated dogs.
    Mizobuchi M; Hineno T; Kakimoto Y; Hiratani K
    Brain Res; 1993 May; 612(1-2):319-21. PubMed ID: 8101134
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice.
    Yarkov AV; Hanger D; Reploge M; Joyce JN
    Pharmacol Biochem Behav; 2003 Dec; 76(3-4):551-62. PubMed ID: 14643855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.
    Blanchet PJ; Grondin R; Bédard PJ; Shiosaki K; Britton DR
    Eur J Pharmacol; 1996 Aug; 309(1):13-20. PubMed ID: 8864687
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
    Muralikrishnan D; Mohanakumar KP
    FASEB J; 1998 Jul; 12(10):905-12. PubMed ID: 9657530
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson's disease.
    Wang Y; Yu X; Zhang P; Ma Y; Wang L; Xu H; Sui D
    J Pharmacol Sci; 2018 Sep; 138(1):31-37. PubMed ID: 30241783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
    Blanchet PJ; Grondin R; Bédard PJ
    Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Frontal cognitive impairments and saccadic deficits in low-dose MPTP-treated monkeys.
    Slovin H; Abeles M; Vaadia E; Haalman I; Prut Y; Bergman H
    J Neurophysiol; 1999 Feb; 81(2):858-74. PubMed ID: 10036286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.